BioVersys Opens European IPO Season

On 7 February 2025, BioVersys, a leading Swiss biopharmaceuticals company, went public on SIX Swiss Exchange, ringing in this year’s IPO season in Switzerland. At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys was around CHF 216 million.

Established in 2008, BioVersys specialises in the research and development of novel anti-bacterial products for life threatening infections caused by multi-drug resistant bacteria.

These include BV100 and Alpibectir, two drug candidates which address two of the top three priorities of the World Health Organisation for bacterial pathogens to prevent a global health crisis.

“It is a ringing endorsement of the strength of our local market when a leading biopharmaceuticals company specialising in the treatment of life-threatening infectious diseases like BioVersys, chooses to list on SIX Swiss Exchange. By listing on SIX Swiss Exchange, BioVersys will be able to raise its profile with a broader investor base to further fuel its exciting product pipeline and growth ambitions,” said  Bjørn Sibbern, CEO of SIX.

BioVersys CEO Marc Gitzinger says: “Today marks a major milestone for BioVersys as we take the next step in our growth strategy. We are truly encouraged by the positive demand and strong investor interest we have received over the past weeks. This support enables us to move full speed ahead with our clinical trials and pipeline of drug candidates, as we remain fully committed to bringing urgently needed new antibiotics to severely ill patients worldwide. I want to extend my sincere gratitude to everyone who has contributed to this achievement – our dedicated employees, partners, shareholders, and all stakeholders who share our vision. A special thanks to SIX Swiss Exchange and the Swiss biotech ecosystem, which provide the key ingredients for successful IPOs.”

With this transaction, SIX is confirming its position as the leading European exchange operator for companies in the healthcare sector.

The BioVersys IPO is the first IPO for Switzerland in 2025, and it will hopefully be followed by more listings as the year progresses.

“Challenging market conditions, namely rising interest rates and inflation, created an environment over the last few years which was not particularly attractive for IPOs in Europe, or globally. Now that markets are stabilizing, IPOs are likely to regain momentum. After a strong finish last year in Switzerland and Spain, we look forward to welcoming even more companies onto the Exchange in 2025,” commented Sibbern.